Press Releases

• ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) — June 17, 2010
  [ HTML | PDF ]

• ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur of the Year 2010 Award Finalist in Northern California — May 19, 2010
  [ HTML | PDF ]

• ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference — May 4, 2010
  [ HTML | PDF ]

• ChemoCentryx Identifies Novel Small Molecule ChemR23 Antagonist for the Treatment of Inflammatory Diseases — April 8, 2010
  [ HTML | PDF ]

• ChemoCentryx Announces Phase II Clinical Trial of CCX140, a Novel, Orally-Available Small Molecule Antagonist of Chemokine Receptor CCR2 — March 22, 2010
  [ HTML | PDF ]

• ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases — January 28, 2010
  [ HTML | PDF ]

• ChemoCentryx Appoints Geoffrey M. Parker to Company's Board of Directors — January 12, 2010
  [ HTML | PDF ]

• GSK Exercises Option to Progress Development of ChemoCentryx's Traficet-EN for the Treatment of Inflammatory Bowel Diseases — January 11, 2010
  [ HTML | PDF ]

• ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis — December 16, 2009
  [ HTML | PDF ]

• ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease — December 7, 2009
  [ HTML | PDF ]

• ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN™ at the GASTRO 2009 UEGW/WCOG Conference — November 25, 2009
  [ HTML | PDF ]

• ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan — July 8, 2009
  [ HTML | PDF ]

• PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN™ Presented in Oral Session at DDW 2009 Conference — June 1, 2009
  [ HTML | PDF ]

• ChemoCentryx's Traficet-EN™ Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week — May 19, 2009
  [ HTML | PDF ]

• ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist — May 5, 2009
  [ HTML | PDF ]

• ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 into Clinical Development — October 15, 2008
  [ HTML | PDF ]

• ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN™ ) in Crohn's Disease — June 12, 2008
  [ HTML | PDF ]

• ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease — May 13, 2008
  [ HTML | PDF ]

• ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors — January 17, 2008
  [ HTML | PDF ]

• ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth — September 26, 2007
  [ HTML | PDF ]

• ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate — July 24, 2007
  [ HTML | PDF ]

• ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN^™ in Crohn's Disease at the Digestive Disease Week 2007 Conference — May 23, 2007
  [ HTML | PDF ]

• ChemoCentryx's Traficet-EN^™ Phase 2 Data in Crohn's Disease Accepted for Oral Presentation and Highlighted in "Best of UEGW" Session at DDW 2007 — May 17, 2007
  [ HTML | PDF ]

• ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery — January 4, 2007
  [ HTML | PDF ]

• ChemoCentryx Presents Clinical and Preclinical Data on Traficet-EN^™ in Inflammatory Bowel Disease (IBD) — December 1, 2006
  [ HTML | PDF ]

• ChemoCentryx Reports Promising Clinical Activity for Traficet-EN^™ from Phase 2 Trial for the Treatment of Crohn's Disease — October 24, 2006
  [ HTML | PDF ]

• GlaxoSmithKline and ChemoCentryx Enter Into Drug Discovery and Development Alliance in Inflammatory Disorders — August 24, 2006
  [ HTML | PDF ]

• ChemoCentryx Completes Series C Financing — August 24, 2006
  [ HTML | PDF ]

• ChemoCentryx Names Regina E. Herzlinger to the Company's Board of Directors — February 7, 2006
  [ HTML | PDF ]

• ChemoCentryx Announces Key Senior Management Team Additions —
  January 5, 2006
  [ HTML | PDF ]

• ChemoCentryx to Initiate Clinical Studies of CCR2 Antagonist CCX915 — November 22, 2005
  [ HTML | PDF ]

• ChemoCentryx Presents Positive Results from Phase 1 Clinical Studies of Traficet-EN^™ at Digestive Disease Week Meeting — May 16, 2005
  [ HTML | PDF ]

• ChemoCentryx Initiates Phase II Clinical Trial of Traficet-EN^™ in Inflammatory Bowel Disease — January 6, 2005
  [ HTML | PDF ]

• ChemoCentryx Raises $33 Million in Private Financing — June 17, 2004
  [ HTML | PDF ]

• ChemoCentryx and Forest Laboratories to Collaborate on the Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics — March 15, 2004
  [ HTML | PDF ]

• ChemoCentryx Begins Phase I Clinical Trial of Traficet-EN^™, a Novel Drug Candidate for the Treatment of Inflammatory Bowel Disease — January 13, 2004
  [ HTML | PDF ]

• ChemoCentryx Awarded $14 Million NIH Grant to Develop Chemokine-Based Immunomodulators — October 13, 2003
  [ HTML | PDF ]

• ChemoCentryx Announces Initiation of Phase I Clinical Trial by Tularik — September 17, 2002
  [ HTML | PDF ]